Novartis AG (MEX:NOVNN) Cyclically Adjusted Book per Share: MXN492.84 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NOVNN Novartis AG MEX:NOVNN
80 GF Score
Price MXN2,487.40
GF Value MXN2,044.52
! 7 Warning Signs
View Full Analysis

What is Novartis AG Cyclically Adjusted Book per Share?

Novartis AG MEX:NOVNN 80 Cyclically Adjusted Book per Share is MXN492.84 as of Jun. 2026. GuruFocus rates MEX:NOVNN with a GF Score™ of 80/100 and a GF Value™ of MXN2,044.52. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Novartis AG's adjusted book value per share for the three months ended in Jun. 2026 was MXN381.365. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN492.84 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Novartis AG's average Cyclically Adjusted Book Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -3.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -0.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Novartis AG was 4.60% per year. The lowest was -3.20% per year. And the median was 2.70% per year.

As of today (2026-07-24), Novartis AG's current stock price is MXN2487.40. Novartis AG's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was MXN492.84. Novartis AG's Cyclically Adjusted PB Ratio of today is 5.05.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novartis AG was 5.11. The lowest was 2.23. And the median was 2.84.


Novartis AG  (MEX:NOVNN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Novartis AG's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2487.40/492.84
=5.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novartis AG was 5.11. The lowest was 2.23. And the median was 2.84.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Novartis AG Cyclically Adjusted Book per Share Related Terms


Novartis AG Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Novartis AG's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Cyclically Adjusted Book per Share Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 590.13 534.43 681.89 568.04

Novartis AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 608.54 586.92 568.04 578.30 492.84

MEX:NOVNN vs LLY, JNJ, ABBV: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PB Ratio falls into.


MEX:NOVNN
80GF Score
Novartis AG MEX:NOVNN
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis AG Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novartis AG's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=381.365/108.5400*108.5400
=381.365

Current CPI (Jun. 2026) = 108.5400.

Novartis AG Quarterly Data

Book Value per Share CPI Adj_Book
201609 610.336 99.604 665.092
201612 649.862 99.380 709.764
201703 537.951 100.040 583.659
201706 539.441 100.285 583.844
201709 566.268 100.254 613.073
201712 628.544 100.213 680.772
201803 554.179 100.836 596.521
201806 650.089 101.435 695.624
201809 631.095 101.246 676.564
201812 667.880 100.906 718.408
201903 394.411 101.571 421.473
201906 431.036 102.044 458.476
201909 457.886 101.396 490.148
201912 461.914 101.063 496.087
202003 521.512 101.048 560.181
202006 542.641 100.743 584.638
202009 529.174 100.585 571.027
202012 498.864 100.241 540.167
202103 460.000 100.800 495.322
202106 480.950 101.352 515.059
202109 521.805 101.533 557.819
202112 620.990 101.776 662.264
202203 553.797 103.205 582.425
202206 579.958 104.783 600.754
202209 568.756 104.835 588.858
202212 545.823 104.666 566.024
202303 447.479 106.245 457.146
202306 429.761 106.576 437.683
202309 323.419 106.570 329.399
202312 387.536 106.461 395.103
202403 322.709 107.355 326.271
202406 377.635 107.991 379.555
202409 426.618 107.468 430.874
202412 465.098 107.128 471.228
202503 400.643 107.722 403.684
202506 408.370 108.075 410.127
202509 423.807 107.710 427.073
202512 435.292 107.200 440.733
202603 363.963 108.060 365.580
202606 381.365 108.540 381.365

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of MXN492.84 mean?
Novartis AG (MEX:NOVNN) has a Cyclically Adjusted Book per Share of MXN492.84 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novartis AG and its competitors.
Is Novartis AG's Cyclically Adjusted Book per Share too high?
Novartis AG's current Cyclically Adjusted Book per Share is MXN492.84. Overall, Novartis AG has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Cyclically Adjusted Book per Share compare to LLY and JNJ?
Novartis AG's Cyclically Adjusted Book per Share of MXN492.84 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novartis AG and its competitors. Novartis AG's current Cyclically Adjusted Book per Share is MXN492.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Novartis AG (MEX:NOVNN) has a current Cyclically Adjusted Book per Share of MXN492.84. The stock's GF Value™ is MXN2,044.52, compared to a current price of MXN2,487.40 — trading 21.7% above its estimated fair value. The current Cyclically Adjusted Book per Share is MXN492.84. Novartis AG's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Novartis AG (MEX:NOVNN), the current Cyclically Adjusted Book per Share is MXN492.84 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (MEX:NOVNN) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of MXN2,487.40 is trading 21.7% above its estimated GF Value™ of MXN2,044.52.

Key valuation signals for MEX:NOVNN:

  • Cyclically Adjusted Book per Share: MXN492.84
  • GF Value™: MXN2,044.52 vs. price of MXN2,487.40 (21.7% above fair value)
  • GF Score™: 80/100 with 7 warning signs

No single metric tells the full story. See the MEX:NOVNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
80GF Score

Get the complete analysis for MEX:NOVNN

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,487.40
Price
MXN2,044.52
GF Value